Match!
Linda E. Dean
University of Aberdeen
Physical therapyRheumatologyAnkylosing spondylitisFibromyalgiaMedicine
47Publications
9H-index
554Citations
What is this?
Publications 29
Newest
Objective To examine differences in clinical and patient-reported outcomes, including work, in individuals with axial spondyloarthritis (axSpA) living in rural and urban settings. Methods Using a sequential, explanatory mixed-method design, data from the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis were used to (1) characterise participants with axSpA living in rural and urban areas and (b) assess any differences in outcome after commencement of biologic therapy...
Source
#1Joanna Shim (Aberd.: University of Aberdeen)H-Index: 3
#2Linda E. Dean (Aberd.: University of Aberdeen)H-Index: 9
Last. Neil Basu (Glas.: University of Glasgow)H-Index: 18
view all 6 authors...
OBJECTIVES: Effective management of axial spondyloarthritis (axSpA)-related fatigue is a major unmet clinical need. Anti-TNF therapy may reduce fatigue levels, although any effect has yet to be definitively quantified and predictors of any such improvements are unknown. METHODS: The British Society of Rheumatology Register in Axial Spondyloarthritis (BSRBR-AS) prospectively recruited axSpA patients across the UK. Changes in fatigue levels (measured using the Chalder Fatigue Scale) >1 year were c...
Source
#1Gareth T. Jones (Aberd.: University of Aberdeen)H-Index: 57
#2Linda E. Dean (Aberd.: University of Aberdeen)H-Index: 9
Last. Gary J. Macfarlane (Aberd.: University of Aberdeen)H-Index: 78
view all 5 authors...
Management guidelines assume that results from clinical trials can be generalised, although seldom is data available to test this assumption. We aimed to determine the proportion of patients commencing tumour necrosis factor inhibition (TNFi) who would have been eligible for relevant clinical trials, and whether treatment response differs between these groups and the trials themselves. The British Society for Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS) recruited a real-...
1 CitationsSource
#1Gareth T. Jones (Aberd.: University of Aberdeen)H-Index: 57
#2Linda E. Dean (Aberd.: University of Aberdeen)H-Index: 9
Last. Gary J. Macfarlane (Aberd.: University of Aberdeen)H-Index: 78
view all 4 authors...
Source
#1Linda E. Dean (Aberd.: University of Aberdeen)H-Index: 9
#2Ejaz Pathan (Toronto Western Hospital)H-Index: 5
Last. Gary J. Macfarlane (Aberd.: University of Aberdeen)H-Index: 78
view all 4 authors...
Source
#1Linda E. Dean (Aberd.: University of Aberdeen)H-Index: 9
#2Ovidiu Rotariu (Aberd.: University of Aberdeen)H-Index: 20
Last. Gary J. Macfarlane (Aberd.: University of Aberdeen)H-Index: 78
view all 5 authors...
Source
#1Gary J. Macfarlane (Aberd.: University of Aberdeen)H-Index: 78
#2Ovidiu Rotariu (Aberd.: University of Aberdeen)H-Index: 20
Last. Linda E. Dean (Aberd.: University of Aberdeen)H-Index: 9
view all 5 authors...
Objective To determine modifiable factors associated with poor quality of life (QoL) in patients with axial spondyloarthritis (axSpA). Methods Analysis of data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) and validation of a previous model using data from 1810 patients with axSpA recruited during 2012–2017. Data collected included clinical and patient-reported measures. QoL was assessed using the Ankylosing Spondylitis Quality of Life (ASQoL) ...
1 CitationsSource
#1Gary J. Macfarlane (Aberd.: University of Aberdeen)H-Index: 78
#2Ejaz Pathan (Toronto Western Hospital)H-Index: 5
Last. Linda E. DeanH-Index: 2
view all 4 authors...
OBJECTIVES: While many axSpA patients, eligible to receive anti-TNFalpha therapy, derive benefit when prescribed them, some patients do not. The current study aims to identify modifiable targets to improve outcome as well as non-modifiable targets that identify groups less likely to derive benefit. METHODS: The BSRBR-AS is a prospective cohort study of axSpA patients who, at recruitment, were naive to biologic therapy. Those in the 'biologic' sub-cohort commenced their first anti-TNFalpha therap...
2 CitationsSource
#1Mohammad H. Derakhshan (Glas.: University of Glasgow)H-Index: 25
#2Linda E. Dean (Aberd.: University of Aberdeen)H-Index: 9
Last. Karl Gaffney (NNUH: Norfolk and Norwich University Hospital)H-Index: 13
view all 6 authors...
Background Axial spondyloarthritis (axSpA) is associated with important extra-articular manifestations (EAMS), most notably acute anterior uveitis (AAU), inflammatory bowel disease (IBD) and psoriasis, which may influence the choice of biologic agent used to treat axSpA. Objectives To examine the factors associated with choice of 1st TNF inhibitor (TNFi) for the treatment of axSpA. Methods Clinical and patients-reported outcomes of 2420 patients with axSpA from 83 rheumatology centres in the Uni...
Source
#1Lesley M. Arnold (UC: University of Cincinnati)H-Index: 50
#2Robert M. BennettH-Index: 63
Last. Gary J. Macfarlane (Aberd.: University of Aberdeen)H-Index: 78
view all 12 authors...
Source
123